Literature DB >> 20512480

MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions.

Florian Grabellus1, Margarethe J Konik, Karl Worm, Sien-Yi Sheu, Johannes A P van de Nes, Sebastian Bauer, Werner Paulus, Rupert Egensperger, Kurt W Schmid.   

Abstract

Overexpression of MET and polysomy 7 was formerly demonstrated in chordomas. We investigated mesenchymal-epithelial transition factor (MET) protein expression and copy numbers of chromosome 7 in human chordomas. Furthermore, tumors were screened for gene fusions (PAX3-FKHR, ASPL-TFE3, and SYT-SSX) previously shown to be associated with MET activation in sarcomas. Tissue microarrays (TMAs) were constructed from 66 chordoma samples. MET protein expression was assessed by immunohistochemistry using an immunoreactive score (IRS, scores 0-12). fluorescence in situ hybridization (FISH) with a dual-color DNA probe (7q31) for MET amplification was performed on TMA sections and RT-PCR for PAX3-FKHR, ASPL-TFE3 (type 1 + 2), and SYT-SSX (type 1 + 2) gene fusions on punch biopsies. All tumors (n = 66) expressed MET protein. FISH analysis of 33 tumors lacked MET gene amplification but showed polysomy of chromosome 7 in 15 (45.5%) tumors (13 low and two high polysomies). Although, polysomy 7 showed an increasing incidence with escalating MET IRS, this finding was not statistically significant. PAX3-FKHR, ASPL-TFE3, or SYT-SSX gene fusions were not demonstrable (n = 52). We found MET protein expression in all chordomas. A clear influence of polysomy 7 on MET protein expression could not be statistically demonstrated for this cohort. Moreover, gene fusions with the ability to cause MET overexpression do not occur in chordomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512480     DOI: 10.1007/s13277-010-0021-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

1.  Operative management of sacral chordoma.

Authors:  Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

2.  The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.

Authors:  Erinn Downs-Kelly; Brian J Yoder; Mark Stoler; Raymond R Tubbs; Marek Skacel; Thomas Grogan; Patrick Roche; David G Hicks
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

3.  Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma.

Authors:  Nadia Coltella; Maria Cristina Manara; Vanessa Cerisano; Livio Trusolino; Maria Flavia Di Renzo; Katia Scotlandi; Riccardo Ferracini
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

4.  Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1.

Authors:  S Scheil; S Brüderlein; T Liehr; H Starke; J Herms; M Schulte; P Möller
Journal:  Genes Chromosomes Cancer       Date:  2001-11       Impact factor: 5.006

5.  Imatinib mesylate in chordoma.

Authors:  Paolo G Casali; Antonella Messina; Silvia Stacchiotti; Elena Tamborini; Flavio Crippa; Alessandro Gronchi; Rosaria Orlandi; Carla Ripamonti; Carlo Spreafico; Raffaello Bertieri; Rossella Bertulli; Maurizio Colecchia; Elena Fumagalli; Angela Greco; Federica Grosso; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

Review 6.  Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase.

Authors:  C Birchmeier; E Gherardi
Journal:  Trends Cell Biol       Date:  1998-10       Impact factor: 20.808

7.  Expression of hepatocyte growth factor and c-MET in skull base chordoma.

Authors:  Takahiko Naka; Doerthe Kuester; Carsten Boltze; Stefanie Scheil-Bertram; Amir Samii; Christian Herold; Helmut Ostertag; Sabine Krueger; Albert Roessner
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

Review 8.  Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Authors:  Joseph Paul Eder; George F Vande Woude; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

Review 9.  Drug development of MET inhibitors: targeting oncogene addiction and expedience.

Authors:  Paolo M Comoglio; Silvia Giordano; Livio Trusolino
Journal:  Nat Rev Drug Discov       Date:  2008-06       Impact factor: 84.694

Review 10.  Emerging role of proton beam radiation therapy for chordoma and chondrosarcoma of the skull base.

Authors:  Quynh-Nhu Nguyen; Eric L Chang
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

View more
  7 in total

1.  Regulation of MET-mediated proliferation of thyroid carcinoma cells by miR-449b.

Authors:  Lei Chen; Lei Xu; Gang Wang
Journal:  Tumour Biol       Date:  2015-06-06

2.  Silencing of c-Met by RNA interference inhibits the survival, proliferation, and invasion of nasopharyngeal carcinoma cells.

Authors:  Yuncheng Li; Sulin Zhang; Zhengang Tang; Jian Chen; Weijia Kong
Journal:  Tumour Biol       Date:  2011-09-16

3.  Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation.

Authors:  Mark D Murphey; Matthew J Minn; Alejandro Luiña Contreras; Kelly K Koeller; Robert Y Shih; Carrie Y Inwards; Takehiko Yamaguchi
Journal:  Skeletal Radiol       Date:  2022-09-05       Impact factor: 2.128

Review 4.  Phylooncogenomics: Examining the cancer genome in the context of vertebrate evolution.

Authors:  GuangJun Zhang; Tracy H Vemulapalli; Jer-Yen Yang
Journal:  Appl Transl Genom       Date:  2013-06-29

5.  MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases.

Authors:  Shirong Ma; Linni Fan; Yixiong Liu; Yingmei Wang; Kangjie Yu; Lifeng Wang; Na Fang; Fang Liu; Shuangping Guo; Zhe Wang
Journal:  Diagn Pathol       Date:  2018-08-21       Impact factor: 2.644

6.  MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.

Authors:  Ying Zhang; David Schiff; Deric Park; Roger Abounader
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

7.  Comprehensive analysis of mRNA-lncRNA co-expression profile revealing crucial role of imprinted gene cluster DLK1-MEG3 in chordoma.

Authors:  Hao Chen; Kai Zhang; Jian Lu; Guizhong Wu; Huilin Yang; Kangwu Chen
Journal:  Oncotarget       Date:  2017-11-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.